Clinical Guides
Eczema (Atopic Dermatitis)
A clinically focused guide to diagnosing and managing atopic dermatitis across ages in India, including severity, infection, topical-treatment safety, escalation, allergy-testing limits and pregnancy considerations.
MedNext Academy | 13 min read
Eczema (Atopic Dermatitis)
A clinically focused guide to diagnosing and managing atopic dermatitis across ages in India, including severity, infection, topical-treatment safety, escalation, allergy-testing limits and pregnancy considerations.
Summary
Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterised by itch, xerosis and age-dependent eczematous lesions. The diagnosis is clinical: there is no single confirmatory blood test. Morphology may look less erythematous on deeply pigmented skin, where violaceous, grey-brown or hyperpigmented change, follicular or papular eczema and post-inflammatory dyspigmentation can predominate. Severity must reflect itch, sleep, area, infection, daily function and psychological burden rather than visible redness alone.
Management combines explanation, trigger reduction without indiscriminate avoidance, regular emollient therapy and correctly selected anti-inflammatory treatment. Topical corticosteroids remain effective first-line flare therapy when potency, site, age, amount and duration are matched. Calcineurin inhibitors are useful steroid-sparing options in selected sensitive sites. Wet wraps, phototherapy, systemic immunomodulators and biologic or oral targeted medicines require appropriate expertise and monitoring. Routine antibiotics, antihistamines, food exclusion and allergy panels do not treat uncomplicated eczema.
Crusting, oozing or pustules suggest bacterial infection but colonisation is common and does not itself justify antibiotics. Painful, rapidly worsening monomorphic vesicles or punched-out erosions with fever or malaise suggest eczema herpeticum and require same-day systemic antiviral treatment and specialist assessment. This educational draft does not replace an examined, age-specific prescription and remains reviewed following MedNext Clinical Team review by the MedNext Clinical Team.
How Common Is It?
Atopic dermatitis is common worldwide, begins most often in infancy or childhood and may remit, persist or recur in adult life. Adult-onset disease also occurs. Published prevalence varies substantially with age, diagnostic definition, sampling and geography, so figures from European or North American surveys should not be presented as a current Indian national prevalence. A history of atopic disease in the person or family supports, but is not required for, the diagnosis. Asthma, allergic rhinitis, food allergy and ocular or psychological comorbidity may coexist without proving that an allergen caused every flare.
The burden extends beyond body-surface area. Persistent itch fragments sleep, impairs school and work, increases caregiver workload and can aggravate anxiety, depression and social withdrawal. Hand, facial, eyelid, genital or foot disease may be functionally severe despite limited area. In darker skin, inflammation may be underestimated if assessment relies on redness; palpation, surface change, excoriation, lichenification, sleep and patient-reported symptoms become especially important. Residual lighter or darker pigmentation can remain after inflammation settles and should not automatically trigger stronger anti-inflammatory treatment.
Indian access is heterogeneous. Humidity, heat, sweating, air pollution, hard water, occupational wet work, crowded living conditions and variable medicine availability can influence practical care, but none is a universal cause. Treatment cost, travel, refrigeration or laboratory monitoring may determine whether advanced therapy is sustainable. A useful prevalence statement therefore acknowledges commonness and burden without converting a foreign estimate into an individual prediction.
Risk Factors
Atopic dermatitis reflects epidermal-barrier dysfunction, immune dysregulation and environmental interaction. Early onset, family history of atopy and some genetic barrier variants increase susceptibility, but genetic testing is not routine clinical care. Dry climate, frequent detergent exposure, fragranced products, rough fabrics, heat, sweating, saliva, repeated rubbing and occupational wet work may aggravate an established disorder. The relevant trigger is reproducible in that individual; long speculative lists can create costly restrictions without improving disease. Stress can intensify itch and scratching, but describing eczema as purely psychological is inaccurate and stigmatising.
Food allergy is more likely in young children with immediate reproducible symptoms or persistent moderate-to-severe eczema despite correctly delivered treatment. Eczema alone does not justify broad IgE panels. Sensitisation on a test is not the same as clinical allergy, and unsupervised elimination risks protein-energy and micronutrient deficiency. Airborne or contact allergy is considered when distribution and chronology fit, such as persistent eyelid, facial, hand or occupational dermatitis. Patch testing assesses delayed contact allergy; skin-prick or specific-IgE testing addresses immediate sensitisation and answers a different question.
Secondary infection risk rises when skin is fissured, excoriated or undertreated. Previous eczema herpeticum is important because recurrence can be serious. Topical-treatment adverse effects are more likely with unnecessarily potent steroids, prolonged continuous use, occlusion or thin-skin sites. Conversely, steroid fear and under-treatment prolong inflammation and infection risk. Pregnancy can alter disease activity, but pregnancy itself does not establish a new eczema diagnosis; scabies, drug eruption and pregnancy-specific dermatoses may need consideration.
Diagnosis
History
Ask about onset, recurrence, itch, sleep, morphology and distribution over time; treatment response; personal or family atopy; occupational and household exposures; skin-care products; immediate food reactions; infection; and quality-of-life effects. Establish exactly which preparations were used, their potency, amount, site, frequency and duration before declaring treatment failure. Sudden painful deterioration, fever, clustered blisters or punched-out erosions changes urgency. In infants ask about feeding, growth and truly immediate allergy symptoms; in adults ask about hand exposure, contact allergens and new medicines.
Examination
Examine the whole skin in good light. Record xerosis, excoriation, papules or plaques, lichenification, fissuring, oozing, crust, vesicles and pigment change, noting age-specific flexural, facial, extensor, hand or nipple patterns. On deeply pigmented skin assess texture, warmth, swelling and symptoms as well as colour. Look for scabies burrows, sharply demarcated contact patterns, annular fungal edges, psoriasis morphology and signs of bacterial or herpetic infection. Severity includes extent, intensity, sleep and function; a validated tool such as EASI, SCORAD or POEM can support monitoring but does not replace clinical judgment.
Investigations
Most cases need none. Swab when infection is severe, recurrent, unusual or failing empiric treatment, while recognising colonisation. Viral PCR or swab can support suspected herpes but treatment must not wait when eczema herpeticum is clinically likely. Directed patch testing, skin-prick testing or specific IgE follows a focused history and specialist interpretation. Biopsy, fungal microscopy or immune evaluation is reserved for diagnostic uncertainty or atypical recurrent infection, not routine screening.
Differential Diagnosis
Irritant contact dermatitis follows cumulative wet work, soaps, detergents, friction or occlusion and commonly affects hands; atopic barrier impairment may coexist. Allergic contact dermatitis is suggested by exposure-linked, persistent or anatomically patterned disease, including eyelid, facial, hand, footwear or topical-medicament eczema. Patch testing is useful when this delayed mechanism is suspected. Seborrhoeic dermatitis favours scalp, eyebrows, nasolabial folds and presternal areas with greasy scale. Psoriasis tends to form well-demarcated plaques and may involve scalp, nails or extensor surfaces, although overlap occurs.
Scabies causes nocturnal itch, affected contacts and lesions at finger webs, wrists, axillae, waist, genitalia or infant palms and soles; eczema can obscure burrows. Tinea may have an advancing scaly border and can be distorted by topical steroid use. Impetigo produces superficial crusting, while bacterial infection of eczema usually accompanies a flare. Eczema herpeticum produces painful, rapidly disseminating monomorphic vesicles or punched-out erosions and systemic illness; it must not be dismissed as ordinary weeping eczema.
In infants consider seborrhoeic dermatitis, scabies, nutritional deficiency, immunodeficiency and rare genodermatoses when growth, infection pattern or morphology is atypical. In adults consider cutaneous T-cell lymphoma when new, persistent, treatment-resistant patches or plaques have unusual distribution or evolution. Drug eruption, photodermatitis and pregnancy-specific eruptions may mimic eczema. Residual post-inflammatory pigmentation without itch, scale or thickening is not necessarily active dermatitis. Diagnostic reconsideration is safer than repeated escalation when morphology and response do not fit.
Management
Agree measurable goals: less itch and sleep loss, healed fissures, fewer flares and sustainable self-management. Use short, lukewarm washing; avoid harsh detergent cleansers; pat dry; and apply an acceptable fragrance-free emollient generously and repeatedly. Choice depends on dryness, site, climate, preference, cost and adherence. Ointments are more occlusive but may feel uncomfortable in heat or on weeping skin. Emollients remain baseline care during clear periods, while contamination, slipping and paraffin-related fire risk require practical counselling.
Treat active inflammation promptly with a topical corticosteroid of appropriate potency. Mild preparations suit many face or flexural flares; thicker skin and severe short courses may need greater potency under supervision. Demonstrate fingertip-unit dosing and distinguish expected transient effects from harms of prolonged misuse. Intermittent proactive treatment to recurrent sites can reduce flares after control. Tacrolimus or pimecrolimus can spare steroid on sensitive sites or in selected persistent disease; initial burning is common, and age/licensing and infection status must be checked. Wet-wrap therapy can help selected severe flares but increases absorption and needs instruction.
If diagnosis, technique and adherence are sound yet disease remains burdensome, refer for phototherapy or systemic treatment. Options include conventional immunosuppressants, biologics and oral JAK inhibitors; selection depends on age, phenotype, comorbidity, infection risk, pregnancy plans, monitoring, availability and cost. AAD recommendations support several advanced therapies but are not an Indian formulary. Systemic corticosteroids are generally unsuitable for chronic control because rebound and cumulative toxicity outweigh short-lived benefit.
Prescribing Information
A topical plan must name the product or generic drug, potency, vehicle, body site, frequency, duration, quantity and what to do when controlled. Labels such as mild, moderate, potent and very potent are not interchangeable with percentage strength: different molecules have different potency. Use the least potent preparation likely to control the site, but avoid ineffective token dosing. Thin skin, face, eyelids, folds, genital skin, infants and occlusion need extra caution. Local adverse effects include atrophy, striae, telangiectasia, acneiform change and periorificial dermatitis; clinically important systemic absorption is uncommon with appropriate use but risk rises with high potency, large area and prolonged occlusion.
Topical calcineurin inhibitors do not cause steroid atrophy and may suit face or folds after appropriate assessment. Explain short-lived warmth or burning, avoid application to overt infection, and follow local product age restrictions. Antimicrobials are not routine flare medicines. Treat eczema herpeticum systemically without delay; ocular-area involvement needs ophthalmic input. For suspected bacterial infection, base oral versus topical treatment on extent, systemic illness and antimicrobial policy rather than crust alone. Sedating antihistamines do not treat skin inflammation and should not become chronic sleep medication.
Before phototherapy, systemic immunosuppressants, biologics or JAK inhibitors, specialists screen and monitor according to the exact agent, including infection, vaccination, laboratory and reproductive risks. Pregnancy or breastfeeding requires individualized dermatology-obstetric review; do not stop effective treatment abruptly or assume every topical treatment is unsafe. EuroGuiDerm notes that evidence in pregnancy is limited, so benefit-risk discussion and the least hazardous effective regimen are essential. Availability and approval differ in India.
When to Refer
Arrange routine dermatology referral when the diagnosis is uncertain; facial, eyelid, hand, genital or occupational disease persists; recurrent flares continue despite an adequate documented topical plan; adverse effects or contact allergy are suspected; or phototherapy or systemic treatment may be needed. Referral is also appropriate for severe sleep loss, school or work disruption, depression, treatment fear, recurrent infections or major caregiver burden. Provide the treatment history with potency, amount, adherence and response, not only the phrase refractory eczema. Photographs across time and a symptom score can help establish pattern.
Children need specialist input when severe disease fails optimal topical treatment, growth or nutrition is affected, food allergy is strongly suspected, recurrent deep infections raise concern about immunity, or education and application support have not achieved control. Dietitian and allergy referral should follow a credible clinical question rather than a positive screening panel. Persistent eyelid, facial, hand or footwear eczema may justify patch testing. Suspected occupational disease may require workplace modification and formal occupational-health assessment.
Same-day referral or emergency assessment is required for suspected eczema herpeticum, especially with fever, lethargy, eye-area disease or rapid spread. Severe bacterial infection with systemic illness, extensive skin failure, dehydration, pain out of proportion or concern for sepsis also needs urgent care. Eye pain, photophobia, reduced vision or periocular herpetic lesions requires ophthalmology. Referral urgency must reflect local capability: in India, confirm whether the receiving district hospital, medical college or private service can provide paediatric dermatology, phototherapy, virology or advanced therapy rather than assuming uniform access.
Red Flags
Eczema herpeticum is the key immediately dangerous mimic or complication. Suspect it when a person with eczema develops rapidly worsening painful skin, clusters of similar vesicles, punched-out erosions, haemorrhagic crust, fever or malaise. Start systemic antiviral management through an urgent clinical pathway and obtain same-day specialist advice; do not wait for a swab result. Periocular disease, eye pain, photophobia or visual change requires urgent ophthalmic assessment because keratitis can threaten sight. A history of cold sores may be absent.
Urgent assessment is also needed for extensive spreading erythema, marked tenderness, purulence, fever, hypotension, confusion, dehydration or reduced intake, which can signal serious bacterial infection or sepsis. Pain that is disproportionate, rapidly progressive swelling, bullae or skin necrosis should trigger evaluation for a deeper infection rather than escalating topical steroid. In infants, poor feeding, lethargy, widespread erosions, failure to thrive or recurrent unusual infections warrants paediatric review.
Other safety signals are treatment-related: facial or flexural atrophy, striae, glaucoma symptoms after periocular steroid exposure, systemic illness on immunosuppression, or thrombosis or serious infection symptoms on a JAK inhibitor. Severe sleep deprivation, depression, self-harm thoughts or bullying are clinical harms, not cosmetic concerns. A widespread acute eruption after a new medicine, mucosal involvement, blistering or skin pain may represent a severe drug reaction and is not managed as eczema. Red flags override routine step-up schedules.
Indian Clinical Context
Indian care must accommodate diverse skin pigmentation, climates, cultural skin practices, occupations and access. Erythema can be subtle in brown or black skin; violaceous, grey or dark-brown change, papular or follicular morphology and prominent lichenification may carry the diagnostic signal. Post-inflammatory hyperpigmentation or hypopigmentation is common and may remain after active itch and scale resolve. Explain this trajectory to reduce inappropriate steroid escalation or bleaching-product use. Avoid photographs or severity rules validated only by visible redness without patient symptoms.
Coconut oil or other culturally familiar products may be used by families, but purity, fragrance, contact allergy, occlusion and the difference between a household oil and a tested emollient should be discussed respectfully. Ayurvedic, herbal or combination creams may contain undisclosed potent corticosteroids or sensitising ingredients. Ask non-judgmentally and inspect packaging. Heat and humidity can make greasy ointment unacceptable, so a sustainable vehicle may be better than an theoretically optimal product never used. School, hostel and workplace access to emollients also matters.
Generic topical corticosteroids and calcineurin inhibitors may be available, while phototherapy, patch testing, biologics and JAK inhibitors cluster in larger centres and can create substantial out-of-pocket cost. Drug approval, age indication and monitoring protocols must be checked locally. Infection and scabies remain important mimics; indiscriminate antibiotic-antifungal-steroid combination creams encourage harm. A plan should state affordable alternatives, follow-up, emergency access and who will monitor advanced treatment. International guidelines inform principles but are not automatic Indian prescriptions or reimbursement decisions.
NMC Competency Mapping
The 2024 NMC dermatology curriculum maps this topic most directly to DR12.1, identifying common endogenous and exogenous eczemas from history and clinical features, and DR12.2, providing basic management including topical and systemic therapy. This guide supports those undergraduate outcomes through recognition, initial management, rational topical therapy, counselling and timely referral. A learner should describe the relapsing inflammatory nature of atopic dermatitis; elicit itch, sleep loss, atopic history, exposures, infection and previous-treatment details; and examine morphology and distribution across age and skin colour. The emphasis is clinical reasoning rather than memorising one prevalence or equating every itchy rash with allergy.
Competence includes distinguishing atopic dermatitis from contact dermatitis, scabies, tinea, psoriasis, seborrhoeic dermatitis and drug eruption. The learner should identify bacterial infection and recognise eczema herpeticum as a same-day emergency. They should explain emollient use, fingertip-unit dosing, site-appropriate topical corticosteroid potency, steroid-sparing therapy and why chronic unsupervised combination creams are unsafe. Interpretation of allergy testing must separate sensitisation from disease-causing allergy and protect children from unnecessary exclusion diets.
At higher levels, learners should formulate step-up and step-down plans, assess adherence without blame, document severity and functional burden, and select referral thresholds for phototherapy or systemic therapy. They should understand the broad roles and monitoring burdens of conventional immunosuppressants, biologics and JAK inhibitors without independently initiating them. Pregnancy, childhood growth, mental health and access are integrated professional considerations. Reading this draft does not certify competence in patch testing, paediatric allergy, phototherapy or systemic immunomodulator prescribing; those require supervised training and local protocols.
Key Exam Pearls for NEET PG
Atopic dermatitis is an itchy, chronic or relapsing eczema with xerosis and age-dependent distribution. Infant disease commonly affects cheeks and extensor surfaces while sparing the napkin area; later childhood and adult disease often becomes flexural, although phenotype varies. Lichenification indicates chronic scratching. White dermographism, Dennie-Morgan folds, keratosis pilaris and pityriasis alba may be associated but are not individually diagnostic. Darker skin may show papular, follicular, violaceous or hyperpigmented inflammation and prominent pigment sequelae.
Emollients are foundational even between flares. Topical corticosteroids treat inflammation; choose potency by site, age and severity, then use an adequate amount for a defined interval. Percentage does not equal potency. Tacrolimus and pimecrolimus are steroid-sparing anti-inflammatory options, especially for sensitive sites in appropriate patients. Phototherapy and systemic immunomodulation are specialist escalation. Broad food panels, routine antibiotics, long-term sedating antihistamines and systemic corticosteroid bursts are not routine solutions. Patch testing evaluates delayed contact allergy; prick or specific-IgE testing evaluates immediate sensitisation.
Golden crusting can indicate secondary bacterial infection, but colonisation alone does not require antibiotics. Painful monomorphic vesicles or punched-out erosions with fever suggest eczema herpeticum: systemic antiviral treatment and same-day referral are the exam-critical actions. Scabies, tinea and contact dermatitis are common mimics. Avoid potent topical corticosteroid in an infant or thin-skin area without appropriate supervision. In pregnancy, do not abruptly stop treatment; weigh maternal control and fetal risk with specialist advice because evidence is limited.
Frequently Asked Questions
Are topical corticosteroids unsafe for children or for the face?
They are not inherently unsafe when the correct potency, quantity, site and duration are prescribed and demonstrated. Thin facial skin and infants generally require lower potency and closer review, while potent or prolonged occluded treatment raises risk. Uncontrolled inflammation also causes harm. Families should receive a written plan, fingertip-unit teaching and a review point rather than being told either to avoid all steroids or to use them indefinitely.
Should every child with eczema have food-allergy blood tests?
No. Positive specific-IgE results often show sensitisation rather than a food that causes clinical reactions, and broad panels can lead to nutritionally dangerous exclusion. Testing is directed by a history of immediate reproducible symptoms, growth concerns, or persistent moderate-to-severe eczema despite verified optimal treatment. A specialist should interpret results and supervise any diagnostic elimination and reintroduction, with dietetic support when a major food is removed.
How can eczema herpeticum be distinguished from an ordinary infected flare?
Eczema herpeticum typically causes rapid painful deterioration with crops of similar vesicles or punched-out erosions, often with fever or malaise. Bacterial infection more often produces variable crusting, oozing or pustules, though both can coexist. Suspected eczema herpeticum needs same-day systemic antiviral management and specialist assessment; testing can support the diagnosis but should not delay treatment, especially when lesions approach the eye.
When are biologic medicines or oral JAK inhibitors considered for atopic dermatitis?
They are specialist options for appropriately diagnosed moderate-to-severe disease that remains substantially burdensome after optimized topical care and assessment of adherence, infection and alternative diagnoses. Choice depends on age, comorbidity, pregnancy plans, infection and thrombosis risk, monitoring, approval, affordability and patient preference. Trial efficacy does not mean every medicine is available or appropriate in India, and advanced therapy still requires skin care, safety screening and follow-up.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- a growing library of visual revision sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Clinical GuidesAll Clinical Guides
Browse all clinical management guides for Indian medical practice.
Test your knowledge
Attempt structured MCQs on this topic to consolidate your understanding and connect the guide to exam-focused practice.
Try MCQs on this topic